International Conference on Hepatitis B Viruses

这是一份帮助支付2005年国际乙肝病毒分子生物学会议费用的提案，会议定于9月9日举行。2005年18日至21日。这是自1985年以来连续举行的一系列会议中的下一次会议。这些是该领域的权威年度会议，将乙肝病毒和丁型肝炎病毒(HDV)领域的基础科学家聚集在一起。乙肝病毒仍然是全球和美国的主要公共卫生问题。尽管有预防性疫苗，但需要进行非肠道注射，疫苗失败率为5%-10%。此外，对于超过3.5亿慢性感染者来说， 乙肝疫苗(其中1500多万人同时感染HDV)没有治疗价值。因此，至关重要的是，必须继续进行研究，并促进实地工作人员之间的对话。这是进行这种对话的年度会议。考虑到这一点，并着眼于促进初级研究人员的参与，要求为初级科学家的旅行和参与提供支持。对网站开发的支持也是有限的。今年的会议也得到了乙肝基金会的大力支持，因此，通过使用美国和德国的大学和非营利性工作人员和设施，会议的成本被降至最低。会议将强调通过11个正式的科学会议促进互动和对话，这些会议总是预算用于讨论的时间，以及不那么有条理 “网络”会议。2005年会议的一个主题将是疾病的肝脏免疫细胞生物学以及在其他领域对乙肝病毒和丁型肝炎病毒有用的工具的整合。将通过主旨演讲和特别讲习班促进这一进程。

This is a proposal for help to defray the cost of the 2005 International Molecular Biology of Hepatitis B Virus meetings, scheduled for Sept. 18th through the 21st, 2005. This is the next meeting in a series that has been held continuously since 1985. These are the definitive annual meetings in this field, which bring basic scientists in the field of HBV and hepatitis delta virus (HDV) together. HBV continues to be a major global and US public health problem. Despite a prophylactic vaccine, parenteral injections are needed and there is a vaccine failure rate of 5 - 10%. Moreover, for the more than 350 million people chronically infected with HBV (more than 15 million of whom are co-infected with HDV), the vaccine, is of no therapeutic value. It is thus critical that research continue and dialogue be nurtured between those working in the field. This is the annual meeting at which this dialogue occurs. With this in mind, and an eye on enabling the participation of junior investigators, support for the travel and participation of junior scientists is requested. Limited support for web site development is also needed. This year, the meeting is also strongly supported by the Hepatitis B Foundation, and thus, costs of the meeting are being minimized by using university and non profit staff and facilities in the US and Germany. The meeting will emphasize stimulating interaction and dialogue, through the 11 formal scientific sessions that always budget time for discussion, as well as less structured "networking" sessions. A theme for the 2005 meeting will be the liver immuno-cell-biology of disease and integration of tools useful in other fields to HBV and HDV. This will be facilitated by the keynote addresses and a special workshop.